Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease Virus /von 2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
/in International Publications, Malignant Melanoma /von 2004-10-01 / Cancer Biother. Radiopharm. 2004 Oct;19(5):658-65Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy
/in Gastric Cancer, International Publications /von 2004-10-01 / Cell. Mol. Immunol. 2004 Oct;1(5):351-6Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81Dendritic cell-based immunotherapy in thyroid malignancies
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2004-09-01 / Curr. Drug Targets Immune Endocr. Metabol. Disord. 2004 Sep;4(3):245-51[Immunotherapy–perspectives in therapy of ovarian carcinomas]
/in International Publications, Ovarian Cancer /von 2004-09-01 / Ceska Gynekol 2004 Sep;69(5):372-5A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery
/in Esophageal Carcinoma, Hyperthermia, International Publications /von 2004-09-01 / Int J Hyperthermia 2004 Sep;20(6):647-59The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion model
/in Hyperthermia, International Publications, Malignant Melanoma /von 2004-08-23 / BMC Cancer 2004 Aug;4:53Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination
/in Dendritic Cells, Glioblastoma, International Publications /von 2004-08-15 / Clin. Cancer Res. 2004 Aug;10(16):5316-26
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de